MedTrace Logo

MINIject Glaucoma Implant in European Patients

NCT03624361 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2022-08-09

No results posted yet for this study

Summary

The study will evaluate the efficacy and safety of the MINIject glaucoma implant and Intraocular Pressure (IOP) lowering effects with or without glaucoma medications. The procedure will be a stand-alone surgery. Overall, the patient will be asked to perform several examinations up to 24 months after surgery.

Conditions

  • Glaucoma, Open-Angle
  • Glaucoma Eye
  • Intraocular Pressure

Interventions

DEVICE

Glaucoma device implantation in a stand-alone procedure

MINIject implant is used to reduce intra-ocular pressure in the eye through a minimally-invasive Glaucoma surgical intervention. The intervention is to be performed as stand-alone surgery.

Sponsors & Collaborators

  • iSTAR Medical

    lead INDUSTRY

Principal Investigators

  • Norbert Pfeiffer, Prof. · Universitätsklinikum Mainz

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-23
Primary Completion
2019-12-31
Completion
2021-09-23

Countries

  • France
  • Germany
  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03624361 on ClinicalTrials.gov